EGFR and breast carcinoma: For instance, Lohiya et al. developed a chitosan-coated (pH-responsive), doxorubicin (DOX)-loaded aptamer -MSNs bioconjugate for the active targeting of breast cancer cells overexpressing epidermal growth factor receptor (EGFR/HER2) [59].